Responses
Regular and young investigator award abstracts
Novel single-agent immunotherapies
714 PD1 x TGFβR2 bispecifics selectively block TGFβR2 on PD1-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
